260 related articles for article (PubMed ID: 36705855)
1. Targeted Therapy for MPNs: Going Beyond JAK Inhibitors.
Chen EC; Johnston H; Patel AA
Curr Hematol Malig Rep; 2023 Jun; 18(3):41-55. PubMed ID: 36705855
[TBL] [Abstract][Full Text] [Related]
2. [Novel therapeutics in myeloproliferative neoplasms: beyond JAK inhibitors].
Edahiro Y
Rinsho Ketsueki; 2023; 64(9):970-980. PubMed ID: 37793873
[TBL] [Abstract][Full Text] [Related]
3. Novel Therapies in Myeloproliferative Neoplasms (MPN): Beyond JAK Inhibitors.
Economides MP; Verstovsek S; Pemmaraju N
Curr Hematol Malig Rep; 2019 Oct; 14(5):460-468. PubMed ID: 31372878
[TBL] [Abstract][Full Text] [Related]
4. The Next Generation of JAK Inhibitors: an Update on Fedratinib, Momelotonib, and Pacritinib.
Patel AA; Odenike O
Curr Hematol Malig Rep; 2020 Dec; 15(6):409-418. PubMed ID: 32780250
[TBL] [Abstract][Full Text] [Related]
5. Therapy for myeloproliferative neoplasms: when, which agent, and how?
Geyer HL; Mesa RA
Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):277-86. PubMed ID: 25696867
[TBL] [Abstract][Full Text] [Related]
6. Management of challenging myelofibrosis after JAK inhibitor failure and/or progression.
Scherber RM; Mesa RA
Blood Rev; 2020 Jul; 42():100716. PubMed ID: 32593470
[TBL] [Abstract][Full Text] [Related]
7. Novel treatments for myelofibrosis: beyond JAK inhibitors.
Tremblay D; Mesa R
Int J Hematol; 2022 May; 115(5):645-658. PubMed ID: 35182376
[TBL] [Abstract][Full Text] [Related]
8. Evolving Therapeutic Strategies for the Classic Philadelphia-Negative Myeloproliferative Neoplasms.
Kaplan JB; Stein BL; McMahon B; Giles FJ; Platanias LC
EBioMedicine; 2016 Jan; 3():17-25. PubMed ID: 26870834
[TBL] [Abstract][Full Text] [Related]
9. Novel Therapies in Myelofibrosis: Beyond JAK Inhibitors.
Waksal JA; Mascarenhas J
Curr Hematol Malig Rep; 2022 Oct; 17(5):140-154. PubMed ID: 35984598
[TBL] [Abstract][Full Text] [Related]
10. Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis.
Talpaz M; Kiladjian JJ
Leukemia; 2021 Jan; 35(1):1-17. PubMed ID: 32647323
[TBL] [Abstract][Full Text] [Related]
11. The Rationale for Immunotherapy in Myeloproliferative Neoplasms.
Masarova L; Bose P; Verstovsek S
Curr Hematol Malig Rep; 2019 Aug; 14(4):310-327. PubMed ID: 31228096
[TBL] [Abstract][Full Text] [Related]
12. Targeting the PI3K pathway in myeloproliferative neoplasms.
Gerds AT; Bartalucci N; Assad A; Yacoub A
Expert Rev Anticancer Ther; 2022 Aug; 22(8):835-843. PubMed ID: 35763287
[TBL] [Abstract][Full Text] [Related]
13. Therapy for myeloproliferative neoplasms: when, which agent, and how?
Geyer HL; Mesa RA
Blood; 2014 Dec; 124(24):3529-37. PubMed ID: 25472969
[TBL] [Abstract][Full Text] [Related]
14. Janus kinase inhibitors for the treatment of myeloproliferative neoplasms.
Rosenthal A; Mesa RA
Expert Opin Pharmacother; 2014 Jun; 15(9):1265-76. PubMed ID: 24766055
[TBL] [Abstract][Full Text] [Related]
15. Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.
Bhagwat N; Levine RL; Koppikar P
Int J Hematol; 2013 Jun; 97(6):695-702. PubMed ID: 23670175
[TBL] [Abstract][Full Text] [Related]
16. SOHO State of the Art Updates and Next Questions | Accelerated Phase of MPN: What It Is and What to Do About It.
Patel AA; Odenike O
Clin Lymphoma Myeloma Leuk; 2023 May; 23(5):303-309. PubMed ID: 36907766
[TBL] [Abstract][Full Text] [Related]
17. JAK2 inhibitors in the treatment of myeloproliferative neoplasms.
Tibes R; Bogenberger JM; Geyer HL; Mesa RA
Expert Opin Investig Drugs; 2012 Dec; 21(12):1755-74. PubMed ID: 22991927
[TBL] [Abstract][Full Text] [Related]
18. Novel Therapies in Myeloproliferative Neoplasms: Beyond JAK Inhibitor Monotherapy.
Lee SS; Verstovsek S; Pemmaraju N
J Immunother Precis Oncol; 2021 Aug; 4(3):117-128. PubMed ID: 35663101
[TBL] [Abstract][Full Text] [Related]
19. JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response.
Kleppe M; Kwak M; Koppikar P; Riester M; Keller M; Bastian L; Hricik T; Bhagwat N; McKenney AS; Papalexi E; Abdel-Wahab O; Rampal R; Marubayashi S; Chen JJ; Romanet V; Fridman JS; Bromberg J; Teruya-Feldstein J; Murakami M; Radimerski T; Michor F; Fan R; Levine RL
Cancer Discov; 2015 Mar; 5(3):316-31. PubMed ID: 25572172
[TBL] [Abstract][Full Text] [Related]
20. RAS signaling promotes resistance to JAK inhibitors by suppressing BAD-mediated apoptosis.
Winter PS; Sarosiek KA; Lin KH; Meggendorfer M; Schnittger S; Letai A; Wood KC
Sci Signal; 2014 Dec; 7(357):ra122. PubMed ID: 25538080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
